Additionally, other ongoing trials are evaluating PARP inhibitors in pancreatic ductal adenocarcinoma patients with non-BRCA DNA damage responsive gene deficiencies, as well as PARP inhibitors in combination with other agents (i.e., immune checkpoint inhibitors) to expand the group of patients that might derive benefit from this treatment. The gene discussed is PARP1; the disease is pancreatic ductal adenocarcinoma.